Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Abstract

The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LTβR) as an inhibitor of the lymphotoxin pathway.

1 - 83 . (canceled) 
     
     
         84 . A kit comprising (i) one or more unit doses of a soluble LTβR and (ii) reagents and instructions for how to assay for remyelination. 
     
     
         85 . The kit of  claim 84 , wherein the kit is for the treatment of Multiple Sclerosis. 
     
     
         86 . The kit of  claim 84 , wherein the soluble LTβR is human LTβR or an LT-binding fragment thereof. 
     
     
         87 . The kit of  claim 86 , wherein the soluble LTβR comprises a substantial portion of the extracellular region of human LTβR (SEQ ID NO: 2) linked to an Fc region of an Ig. 
     
     
         88 . The kit of  claim 87 , wherein the soluble LTβR comprises the sequence set forth in SEQ ID NO:1. 
     
     
         89 - 100 . (canceled) 
     
     
         101 . The kit of  claim 84 , further comprising instructions for administering the one or more unit doses of the soluble LTβR to a subject. 
     
     
         102 . The kit of  claim 84 , wherein the kit is for the treatment of a demyelinating disorder. 
     
     
         103 . The kit of  claim 101 , wherein the subject is receiving an anti-TNF therapy. 
     
     
         104 . The kit of  claim 101 , wherein the subject is a human. 
     
     
         105 . The kit of  claim 101 , wherein the instructions provide that the one or more unit doses are administered once every 3-10 days; at least twice and not more than once every 5-20 days; or at least twice and not more than once every 28-31 days. 
     
     
         106 . The kit of  claim 101 , wherein the instructions provide that the one or more unit doses are administered weekly, biweekly or monthly. 
     
     
         107 . The kit of  claim 101 , wherein the instructions provide that the one or more unit doses are administered weekly over the course of at least 4 weeks.